JP2016524914A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016524914A5 JP2016524914A5 JP2016527005A JP2016527005A JP2016524914A5 JP 2016524914 A5 JP2016524914 A5 JP 2016524914A5 JP 2016527005 A JP2016527005 A JP 2016527005A JP 2016527005 A JP2016527005 A JP 2016527005A JP 2016524914 A5 JP2016524914 A5 JP 2016524914A5
- Authority
- JP
- Japan
- Prior art keywords
- hpv
- cells
- specific
- cell population
- fragments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019202239A JP7315435B2 (ja) | 2013-07-15 | 2019-11-07 | 抗ヒトパピローマウイルス抗原ｔ細胞の調製方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361846161P | 2013-07-15 | 2013-07-15 | |
| US61/846,161 | 2013-07-15 | ||
| PCT/US2014/046478 WO2015009604A1 (en) | 2013-07-15 | 2014-07-14 | Methods of preparing anti-human papillomavirus antigen t cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202239A Division JP7315435B2 (ja) | 2013-07-15 | 2019-11-07 | 抗ヒトパピローマウイルス抗原ｔ細胞の調製方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016524914A JP2016524914A (ja) | 2016-08-22 |
| JP2016524914A5 true JP2016524914A5 (https=) | 2017-08-31 |
| JP6616295B2 JP6616295B2 (ja) | 2019-12-04 |
Family
ID=51257632
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016527005A Active JP6616295B2 (ja) | 2013-07-15 | 2014-07-14 | 抗ヒトパピローマウイルス抗原ｔ細胞の調製方法 |
| JP2019202239A Active JP7315435B2 (ja) | 2013-07-15 | 2019-11-07 | 抗ヒトパピローマウイルス抗原ｔ細胞の調製方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019202239A Active JP7315435B2 (ja) | 2013-07-15 | 2019-11-07 | 抗ヒトパピローマウイルス抗原ｔ細胞の調製方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (8) | US20160144018A1 (https=) |
| EP (3) | EP4137564B1 (https=) |
| JP (2) | JP6616295B2 (https=) |
| CN (2) | CN105452448B (https=) |
| AU (4) | AU2014290286A1 (https=) |
| CA (1) | CA2918080A1 (https=) |
| ES (3) | ES2932429T3 (https=) |
| RU (1) | RU2713333C2 (https=) |
| WO (1) | WO2015009604A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10828353B2 (en) * | 2015-01-31 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for T cell delivery of therapeutic molecules |
| WO2017049237A1 (en) * | 2015-09-18 | 2017-03-23 | The General Hospital Corporation Dba Massachusetts General Hospital | Personalized approach to dosage of anti-fugetactic agent for treatment of cancer |
| CN108289913A (zh) | 2015-10-30 | 2018-07-17 | 儿童国家医疗中心 | 从未致敏t细胞群体产生hpv抗原特异性t细胞 |
| JP7019578B2 (ja) * | 2015-12-30 | 2022-02-15 | セルジーン コーポレイション | Ｔリンパ球の産生方法及びそれにより産生されるｔリンパ球 |
| MX2019003768A (es) | 2016-10-03 | 2019-06-24 | Juno Therapeutics Inc | Moleculas de enlace especificas de hpv. |
| HUE066460T2 (hu) | 2016-10-26 | 2024-08-28 | Iovance Biotherapeutics Inc | A kriokonzervált tumor infiltráló limfociták restimulációja |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| RU2769474C2 (ru) * | 2017-01-20 | 2022-04-01 | Атара Байотерапьютикс, Инк. | Способы лечения рассеянного склероза с использованием аутологичных т-клеток |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| AR112072A1 (es) | 2017-06-05 | 2019-09-18 | Iovance Biotherapeutics Inc | Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario |
| JP2020537515A (ja) | 2017-10-03 | 2020-12-24 | ジュノー セラピューティクス インコーポレイテッド | Ｈｐｖ特異的結合分子 |
| EP3737743A1 (en) | 2018-01-08 | 2020-11-18 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| CA3094468A1 (en) | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
| EP3773908A1 (en) | 2018-04-05 | 2021-02-17 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
| MA52207A (fr) | 2018-04-05 | 2021-02-17 | Editas Medicine Inc | Lymphocytes t exprimant un récepteur recombinant, polynucléotides et procédés associés |
| WO2019196088A1 (en) * | 2018-04-13 | 2019-10-17 | Syz Cell Therapy Co. | Methods of obtaining tumor-specific t cell receptors |
| WO2019210131A1 (en) | 2018-04-27 | 2019-10-31 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| WO2019217753A1 (en) | 2018-05-10 | 2019-11-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| US12516099B2 (en) | 2018-08-09 | 2026-01-06 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| SG11202102108QA (en) | 2018-09-11 | 2021-04-29 | Juno Therapeutics Inc | Methods for mass spectrometry analysis of engineered cell compositions |
| MY210603A (en) | 2018-11-05 | 2025-10-01 | Iovance Biotherapeutics Inc | Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| US12611427B2 (en) | 2018-11-05 | 2026-04-28 | Iovance Biotherapeutics, Inc. | Treatment of NSCLC patients refractory for anti-PD-1 antibody |
| GB201821207D0 (en) | 2018-12-24 | 2019-02-06 | Tcer Ab | Immunotherapy therapy |
| WO2020223535A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
| BR112022011795A2 (pt) | 2019-12-20 | 2022-08-30 | Instil Bio Uk Ltd | Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos |
| JP2023531531A (ja) | 2020-06-26 | 2023-07-24 | ジュノ セラピューティクス ゲーエムベーハー | 組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法 |
| JP2023546359A (ja) | 2020-10-06 | 2023-11-02 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療 |
| JP2024512029A (ja) | 2021-03-25 | 2024-03-18 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用 |
| WO2023196884A1 (en) | 2022-04-06 | 2023-10-12 | Juno Therapeutics, Inc. | Detection assay for human papillomavirus (hpv) type 16 (hpv-16) |
| JP2025512401A (ja) | 2022-04-15 | 2025-04-17 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 特定のサイトカインの組み合わせ及び／またはＡＫＴｉ処理を使用したＴＩＬ拡張プロセス |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| CN1609196A (zh) * | 2003-10-17 | 2005-04-27 | 上海普泛生物科技有限公司 | 用于发现肿瘤特异性抗原和肿瘤特异性抗原决定簇的高产率t淋巴细胞克隆技术 |
| WO2009102697A2 (en) * | 2008-02-11 | 2009-08-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of obtaining antigen-specific t cell populations |
| US8383099B2 (en) * | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20120244133A1 (en) * | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| CN102816734A (zh) * | 2012-05-09 | 2012-12-12 | 阮润生 | 一种肿瘤抗原特异性t细胞的获取方法 |
-
2014
- 2014-07-14 ES ES19209253T patent/ES2932429T3/es active Active
- 2014-07-14 EP EP22197914.9A patent/EP4137564B1/en active Active
- 2014-07-14 EP EP19209253.4A patent/EP3626817B1/en active Active
- 2014-07-14 WO PCT/US2014/046478 patent/WO2015009604A1/en not_active Ceased
- 2014-07-14 CN CN201480044285.7A patent/CN105452448B/zh active Active
- 2014-07-14 ES ES22197914T patent/ES3034357T3/es active Active
- 2014-07-14 CN CN202010606868.1A patent/CN111733131A/zh active Pending
- 2014-07-14 AU AU2014290286A patent/AU2014290286A1/en not_active Abandoned
- 2014-07-14 JP JP2016527005A patent/JP6616295B2/ja active Active
- 2014-07-14 US US14/905,138 patent/US20160144018A1/en not_active Abandoned
- 2014-07-14 RU RU2016103614A patent/RU2713333C2/ru active
- 2014-07-14 CA CA2918080A patent/CA2918080A1/en active Pending
- 2014-07-14 ES ES14745056T patent/ES2773548T3/es active Active
- 2014-07-14 EP EP14745056.3A patent/EP3022294B1/en active Active
-
2018
- 2018-12-13 US US16/218,658 patent/US20190117761A1/en not_active Abandoned
-
2019
- 2019-11-07 JP JP2019202239A patent/JP7315435B2/ja active Active
-
2020
- 2020-09-16 AU AU2020233702A patent/AU2020233702B2/en active Active
- 2020-12-07 US US17/113,570 patent/US11077182B2/en active Active
-
2021
- 2021-07-12 US US17/372,927 patent/US11376318B2/en active Active
- 2021-07-12 US US17/373,093 patent/US11331385B2/en active Active
- 2021-07-12 US US17/373,130 patent/US11338032B2/en active Active
-
2022
- 2022-06-13 US US17/838,662 patent/US11918640B2/en active Active
-
2023
- 2023-09-22 AU AU2023233209A patent/AU2023233209B2/en active Active
-
2024
- 2024-02-01 US US18/430,031 patent/US20240382577A1/en active Pending
-
2026
- 2026-01-15 AU AU2026200282A patent/AU2026200282A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016524914A5 (https=) | ||
| RU2016103614A (ru) | Способы получения т-клеток против антигена папилломавируса человека | |
| Tran et al. | Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy | |
| JP2016509840A5 (https=) | ||
| JP2012521215A5 (https=) | ||
| MY180750A (en) | Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy | |
| JP2014087372A5 (https=) | ||
| Klein et al. | EBV genome carrying B lymphocytes that express the nuclear protein EBNA-2 but not LMP-1: Type IIb latency | |
| CN109609451B (zh) | 体外快速扩增肾癌的肿瘤浸润淋巴细胞的方法 | |
| Ge et al. | Potential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy | |
| Chen et al. | Blocking IL-10 signalling at the time of immunization renders the tumour more accessible to T cell infiltration in mice | |
| EP4269595A3 (en) | Methods for selectively expanding cells expressing a tcr with a murine constant region | |
| JP2019508056A5 (https=) | ||
| CN109294998B (zh) | 一种rff1细胞 | |
| Klein et al. | Restricted expression of EBV encoded proteins in in vitro infected CLL cells | |
| HK40088479A (en) | Methods of preparing anti-human papillomavirus antigen t cells | |
| CN120796184A (zh) | 一种用于扩增多能干细胞来源的nk细胞的非细胞刺激剂 | |
| CN103525764A (zh) | 培养树突状杀手细胞的配方及其方法 | |
| Xu et al. | CD8+ memory T-cell inflation renders compromised CD4+ T-cell-dependent CD8+ T-cell immunity via naïve T-cell anergy | |
| Tano et al. | Enhancement of the T cell-stimulating ability of dendritic cells by 5-FU via regulation of the expression of ligands for programed cell death 1. | |
| Mohs et al. | Blockage of CCL5/RANTES modifies immune infiltration and the inflammatory milieu during chronic liver disease: 65 | |
| HK40025869B (en) | Methods of preparing anti-human papillomavirus antigen t cells | |
| Cho et al. | CT7 (MAGE-C1)-Specific Cellular Immune Responses in the Bone Marrow Microenvironment of Multiple Myeloma Patients. | |
| Blackmore et al. | Patients with alcoholic hepatitis present strong Th1 cellular immune responses to alcohol dehydrogenase, which are related to impairment of the PD-1/PD-L1 pathway: 64 | |
| Carey et al. | 773 RS12979860 CC GENOTYPE IS ASSOCIATED WITH BASELINE HIGH NUMBERS OF CD56BRIGHT NK-CELLS, LOW NUMBERS OF CD3-CD56-CD16–CELLS, LOW IL-10 HCV-SPECIFIC PRODUCTION IN CH-C THERAPY RESPONDERS |